Seres Therapeutics Stock Shares Outstanding
| MCRB Stock | USD 0.71 0.02 2.74% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
The current year's Common Stock Shares Outstanding is expected to grow to about 163.2 M. Seres | Shares Outstanding |
Seres Therapeutics Company Shares Outstanding Analysis
Seres Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Seres Therapeutics Shares Outstanding | 174.36 M |
Most of Seres Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Seres Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Seres Therapeutics is extremely important. It helps to project a fair market value of Seres Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Seres Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Seres Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Seres Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Seres Shares Outstanding Historical Pattern
Today, most investors in Seres Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Seres Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Seres Therapeutics shares outstanding as a starting point in their analysis.
Seres Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Seres Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Seres Therapeutics has 174.36 M of shares currently outstending. This is 3.42% lower than that of the Biotechnology sector and 63.17% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 69.51% higher than that of the company.
Seres Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in shares outstanding category among its peers.
Seres Fundamentals
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 184.43 M | ||||
| Shares Outstanding | 174.36 M | ||||
| Shares Owned By Insiders | 13.02 % | ||||
| Shares Owned By Institutions | 36.18 % | ||||
| Number Of Shares Shorted | 17.69 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 8.97 X | ||||
| Price To Sales | 390.27 X | ||||
| Gross Profit | (14.53 M) | ||||
| EBITDA | (121.31 M) | ||||
| Net Income | 136 K | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 91.64 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (148.61 M) | ||||
| Short Ratio | 22.25 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Price To Earnings To Growth | (0.11) X | ||||
| Target Price | 3.82 | ||||
| Number Of Employees | 103 | ||||
| Beta | 2.17 | ||||
| Market Capitalization | 128.08 M | ||||
| Total Asset | 139.81 M | ||||
| Retained Earnings | (978.1 M) | ||||
| Working Capital | (2.55 M) | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
| Net Asset | 139.81 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth (0.93) | Return On Assets | Return On Equity |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.